Toxicity and management in CAR T-cell therapy

Molecular Therapy - Oncolytics

Volumn 3, Issue , 2016, Pages 16011-

  Bonifant, Challice L ^a   Jackson, Hollie J ^b   Brentjens, Renier J ^b   Curran, Kevin J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; DEXAMETHASONE; FK 506 BINDING PROTEIN; GANCICLOVIR; TOCILIZUMAB;

ANAPHYLAXIS; ANTIGEN RECOGNITION; CARCINOGENESIS; CARDIOTOXICITY; CELL THERAPY; CYTOKINE RELEASE SYNDROME; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84969244099     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2016.11     Document Type: Review

References (77)

1. Mitchison, NA (1955). Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 102: 157-177.
2. Hinrichs, CS and Rosenberg, SA (2014). Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257: 56-71.
3. Maude, SL, Frey, N, Shaw, PA, Aplenc, R, Barrett, DM, Bunin, NJ et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507-1517.
4. Manzo, T, Heslop, HE and Rooney, CM (2015). Antigen-specific T cell therapies for cancer. Hum Mol Genet 24: R67-R73.
5. Themeli, M, Riviere, I and Sadelain, M (2015). New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16: 357-366.
6. Kolb, HJ (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383.
7. Rosenberg, SA, Restifo, NP, Yang, JC, Morgan, RA and Dudley, ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
8. DiGiusto, D and Cooper, L (2007). Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy 9: 613-629.
9. Hollyman, D, Stefanski, J, Przybylowski, M, Bartido, S, Borquez-Ojeda, O, Taylor, C et al. (2009). Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32: 169-180.
10. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
11. Jin, J, Sabatino, M, Somerville, R, Wilson, JR, Dudley, ME, Stroncek, DF et al. (2012). Simplified method of the growth of human tumor infiltrating lymphocytes in gaspermeable flasks to numbers needed for patient treatment. J Immunother 35: 283-292.
12. Somerville, RP, Devillier, L, Parkhurst, MR, Rosenberg, SA and Dudley, ME (2012). Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVER bioreactor. J Transl Med 10: 69.
13. Sun, J, Huye, LE, Lapteva, N, Mamonkin, M, Hiregange, M, Ballard, B et al. (2015). Early transduction produces highly functional chimeric antigen receptor-modified virusspecific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer 3: 5.
14. Ahmed, N, Brawley, VS, Hegde, M, Robertson, C, Ghazi, A, Gerken, C et al. (2015). Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33: 1688-1696.
15. Eshhar, Z, Waks, T, Gross, G and Schindler, DG (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90: 720-724.
16. Sadelain, M, Riviere, I and Brentjens, R (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3: 35-45.
17. Thomas, S, Hart, DP, Xue, SA, Cesco-Gaspere, M and Stauss, HJ (2007). T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther 7: 1207-1218.
18. Zhou, X, Cui, Y, Huang, X, Yu, Z, Thomas, AM, Ye, Z et al. (2003). Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 14: 1089-1105.
19. Cavalieri, S, Cazzaniga, S, Geuna, M, Magnani, Z, Bordignon, C, Naldini, L et al. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102: 497-505.
20. Casucci, M, Hawkins, RE, Dotti, G and Bondanza, A (2015). Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 64: 123-130.
21. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-935.
22. Scholler, J, Brady, TL, Binder-Scholl, G, Hwang, WT, Plesa, G, Hege, KM et al. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
23. Lee, DW, Gardner, R, Porter, DL, Louis, CU, Ahmed, N, Jensen, M et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195.
24. Chatenoud, L, Ferran, C, Legendre, C, Thouard, I, Merite, S, Reuter, A et al. (1990). In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49: 697-702.
25. Wing, MG, Moreau, T, Greenwood, J, Smith, RM, Hale, G, Isaacs, J et al. (1996). Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98: 2819-2826.
26. Winkler, U, Jensen, M, Manzke, O, Schulz, H, Diehl, V and Engert, A (1999). Cytokinerelease syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224.
27. Suntharalingam, G, Perry, MR, Ward, S, Brett, SJ, Castello-Cortes, A, Brunner, MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
28. Panelli, MC, White, R, Foster, M, Martin, B, Wang, E, Smith, K et al. (2004). Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2: 17.
29. Teachey, DT, Rheingold, SR, Maude, SL, Zugmaier, G, Barrett, DM, Seif, AE et al. (2013). Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121: 5154-5157.
30. Curran, KJ, Pegram, HJ and Brentjens, RJ (2012). Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 14: 405-415.
31. Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6: 224ra25.
32. Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, Cui, YK, Delbrook, C, Feldman, SA et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517-528.
33. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
34. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
35. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
36. Maude, SL, Barrett, D, Teachey, DT and Grupp, SA (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20: 119-122.
37. Buie, LW, Pecoraro, JJ, Horvat, TZ and Daley, RJ (2015). Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann Pharmacother 49: 1057-1067.
38. Topp, MS, Gokbuget, N, Stein, AS, Zugmaier, G, O'Brien, S, Bargou, RC et al. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16: 57-66.
39. Lamers, CH, Sleijfer, S, Vulto, AG, Kruit, WH, Kliffen, M, Debets, R et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-e22.
40. Lamers, CH, Sleijfer, S, van Steenbergen, S, van Elzakker, P, van Krimpen, B, Groot, C et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21: 904-912.
41. Parkhurst, MR, Yang, JC, Langan, RC, Dudley, ME, Nathan, DA, Feldman, SA et al. (2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19: 620-626.
42. Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
43. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
44. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115.
45. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl 16: 1245-1256.
46. Lamers, CH, Willemsen, R, van Elzakker, P, van Steenbergen-Langeveld, S, Broertjes, M, Oosterwijk-Wakka, J et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117: 72-82.
47. Maude, SB, Barrett, DM, Ambrose, DE, Rheingold, SR, Aplenc, R, Teachey, DT et al. (2015). Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/refractory ALL. Blood 126: 683.
48. Maus, MV, Haas, AR, Beatty, GL, Albelda, SM, Levine, BL, Liu, X et al. (2013). T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1: 26-31.
49. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
50. Kohn, DB, Sadelain, M and Glorioso, JC (2003). Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3: 477-488.
51. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
52. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
53. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
54. Kochenderfer, JN, Dudley, ME, Carpenter, RO, Kassim, SH, Rose, JJ, Telford, WG et al. (2013). Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-4139.
55. Cruz, CR, Micklethwaite, KP, Savoldo, B, Ramos, CA, Lam, S, Ku, S et al. (2013). Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122: 2965-2973.
56. Wang, X, Wong, CW, Urak, R, Mardiros, A, Budde, LE, Chang, WC et al. (2015). CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res 21: 2993-3002.
57. Poirot, L, Philip, B, Schiffer-Mannioui, C, Le Clerre, D, Chion-Sotinel, I, Derniame, S et al. (2015). Multiplex genome-edited T-cell manufacturing platform for "Off-the-Shelf" adoptive T-cell immunotherapies. Cancer Res 75: 3853-3864.
58. Cameron, BJ, Gerry, AB, Dukes, J, Harper, JV, Kannan, V, Bianchi, FC et al. (2013). Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5: 197ra103.
59. Linette, GP, Stadtmauer, EA, Maus, MV, Rapoport, AP, Levine, BL, Emery, L et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122: 863-871.
60. Kotter, S, Andresen, C and Kruger, M (2014). Titin: central player of hypertrophic signaling and sarcomeric protein quality control. Biol Chem 395: 1341-1352.
61. Bordignon, C, Bonini, C, Verzeletti, S, Nobili, N, Maggioni, D, Traversari, C et al. (1995). Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6: 813-819.
62. Tiberghien, P, Cahn, JY, Brion, A, Deconinck, E, Racadot, E, Herve, P et al. (1997). Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum Gene Ther 8: 615-624.
63. Bonini, C, Ferrari, G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
64. Thomis, DC, Marktel, S, Bonini, C, Traversari, C, Gilman, M, Bordignon, C et al. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97: 1249-1257.
65. Serafini, M, Manganini, M, Borleri, G, Bonamino, M, Imberti, L, Biondi, A et al. (2004). Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 15: 63-76.
66. Tey, SK, Dotti, G, Rooney, CM, Heslop, HE and Brenner, MK (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transpl 13: 913-924.
67. Wang, X, Chang, WC, Wong, CW, Colcher, D, Sherman, M, Ostberg, JR et al. (2011). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118: 1255-1263.
68. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
69. Marin, V, Cribioli, E, Philip, B, Tettamanti, S, Pizzitola, I, Biondi, A et al. (2012). Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 23: 376-386.
70. Zhou, X, Di Stasi, A, Tey, SK, Krance, RA, Martinez, C, Leung, KS et al. (2014). Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123: 3895-3905.
71. Sato, T, Neschadim, A, Konrad, M, Fowler, DH, Lavie, A and Medin, JA (2007). Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 15: 962-970.
72. Ando, M, Hoyos, V, Yagyu, S, Tao, W, Ramos, CA, Dotti, G et al. (2014). Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther 21: 472-482.
73. Philip, B, Kokalaki, E, Mekkaoui, L, Thomas, S, Straathof, K, Flutter, B et al. (2014). A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124: 1277-1287.
74. Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M and Sadelain, M (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31: 71-75.
75. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
76. Fedorov, VD, Themeli, M and Sadelain, M (2013). PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5: 215ra172.
77. Wu, CY, Roybal, KT, Puchner, EM, Onuffer, J and Lim, WA (2015). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350: aab4077.